Trevi Therapeutics Inc Cash Flow Conversion Efficiency
Trevi Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) has a cash flow conversion efficiency ratio of -0.054x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.43 Million) by net assets ($321.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Trevi Therapeutics Inc (TRVI) market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Trevi Therapeutics Inc (2016–2025)
Cash flow conversion efficiency of Trevi Therapeutics Inc from 2016 to 2025. This chart illustrates how Trevi Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Trevi Therapeutics Inc stock price today for real-time trading data and today's change.
Trevi Therapeutics Inc Cash Flow Conversion Ratio Explained
Trevi Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Trevi Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trevi Therapeutics Inc ranked by their cash flow conversion efficiency. Review financial agility of Trevi Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SolarEdge Technologies Inc
NASDAQ:SEDG
|
0.059x |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
0.008x |
|
SUEDZUCKER UNSP.ADR 1/2
F:SZU1
|
-0.001x |
|
INOX India Limited
NSE:INOXINDIA
|
0.063x |
|
Petrokent Turizm AS
IS:PKENT
|
0.023x |
|
Extendicare Inc
TO:EXE
|
0.146x |
|
AOZORA BANK LTD ADR/20
F:AON0
|
N/A |
|
Zhejiang Kaishan Compressor
SHE:300257
|
0.028x |
Annual Cash Flow Conversion Efficiency for Trevi Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Trevi Therapeutics Inc from 2016 to 2025. Also see balance sheet size of Trevi Therapeutics Inc for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $183.24 Million | $-42.09 Million | -0.230x | +40.17% |
| 2024-12-31 | $99.64 Million | $-38.26 Million | -0.384x | +0.06% |
| 2023-12-31 | $82.55 Million | $-31.71 Million | -0.384x | -46.51% |
| 2022-12-31 | $107.46 Million | $-28.18 Million | -0.262x | +84.53% |
| 2021-12-31 | $17.07 Million | $-28.95 Million | -1.695x | -59.48% |
| 2020-12-31 | $27.28 Million | $-29.00 Million | -1.063x | -151.07% |
| 2019-12-31 | $54.55 Million | $-23.09 Million | -0.423x | +59.94% |
| 2018-12-31 | $17.31 Million | $-18.29 Million | -1.057x | -95.84% |
| 2017-12-31 | $14.78 Million | $-7.97 Million | -0.540x | -183.95% |
| 2016-12-31 | $-17.41 Million | $-11.19 Million | 0.643x | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more